China-based RNA therapeutics startup Ribopeutic has raised nearly RMB 100 million (USD 13.9 million) in Pre-A funding led by Tasly Holding Group and Pan-Lin Asset Management, thus emerging from stealth mode. Founded in 2022 by RNA structure experts, the company combines AI language models with wet-lab validation to identify druggable RNA tertiary structures. Its platform accelerates discovery of small molecules targeting stable RNA folds in central nervous system (CNS) disorders, cancer and autoimmune diseases.

The funding will advance Ribopeutic's lead programs toward Investigational New Drug (IND) applications while expanding its pipeline. Investors highlighted the company's edge in overcoming RNA drug delivery challenges through structural biology insights. Tasly noted AI-driven RNA target discovery could significantly improve development efficiency. Ribopeutic's approach builds on global pharma interest in RNA-targeting small molecules as alternatives to nucleic acid therapies.

According to PharmCube's NextBiopharm® database, there exist six companies currently developing RNA-targeting therapies globally. Click here to request a free trial for NextBiopharm®.